Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Blood Test Helps Identify Depressed Patients

By Labmedica International staff writers
Posted on 14 Feb 2012
Print article
A blood test helps diagnose major depressive disorder (MDD) and could become a useful clinical tool.

The blood test, which analyzes levels of nine biomarkers, accurately distinguished patients diagnosed with depression from control participants. There were no significant false-positive results.

Developed by Ridge Diagnostics (Research Triangle Park, NC, USA), the test measures levels of biomarkers associated with factors such as inflammation, the development and maintenance of neurons, and the interaction between brain structures involved with stress response and other key functions.

The measurements are combined using a specific formula to produce a figure called the MDDScore, a number from 1 to 100 indicating the percentage likelihood that the individual has major depression. In clinical use the MDDScore would range from 1 to 10.

The initial study included 36 adults who had been diagnosed with major depression at the Massachusetts General Hospital (MGH; Boston, MA, USA), Vanderbilt University or Cambridge Health Alliance (Cambridge, MA, USA) and 43 control participants from St. Elizabeth's Hospital (Brighton, MA, USA).

MDDScores for 33 of the 36 patients indicated the presence of depression, while only 8 of the 43 controls had a positive test result. The average score for patients was 85, while the average for controls was 33. A second replication phase study included 34 patients from the MGH and Vanderbilt, 31 of whom had a positive MDDScore result. Combining both groups indicated that the test could accurately diagnose major depression with a sensitivity of about 90 % and a specificity of 80 %.

A report of the studies was published in the December 2011 journal Molecular Psychiatry.

"Traditionally, diagnosis of major depression and other mental disorders has been made based on patients' reported symptoms, but the accuracy of that process varies a great deal, often depending on the experience and resources of the clinician conducting the assessment," said George Papakostas, MD, of the MGH department of Psychiatry, lead and corresponding author of the report. "Adding an objective biological test could improve diagnostic accuracy and may also help us track individual patients' response to treatment."

Antidepressant drugs are the most frequently prescribed medication in the United States today where depression strikes over 19 million adults each year–more than coronary artery disease, cancer, or AIDS. Objective biological test information about depression may aid physicians in the differential diagnosis of MDD, the selection of proper treatment, and effective management of their patients.

Related Links:

Ridge Diagnostics
Massachusetts General Hospital
Cambridge Health Alliance



Print article

Channels

Clinical Chemistry

view channel
Image: Dried blood spots are used to screen newborns for a number of rare inherited conditions. A new dried blood spot screening test has been developed for Niemann-Pick type C, a rare neurodegenerative condition that usually is not diagnosed until after damage to brain cells has begun (Photo courtesy of Washington University School of Medicine).

Newborn Screening Test Developed For Deadly Neurological Disorder

A newborn screening test has been introduced that identifies infants with Niemann-Pick disease type C, an often fatal condition in which cholesterol builds up and eventually destroys brain cells.... Read more

Pathology

view channel
Image: An IsoPSA test for prostate cancer detection and differentiation (Photo courtesy of Dr. Arnon Chait, PhD).

Novel Test Differentiates Malignant Prostate Cancer Grades

A promising new test has been introduced that detects prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein and can also differentiate... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.